These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 25986251)

  • 1. Consensus and differences in primary radiotherapy for localized and locally advanced prostate cancer in Switzerland: A survey on patterns of practice.
    Panje CM; Dal Pra A; Zilli T; R Zwahlen D; Papachristofilou A; Herrera FG; Matzinger O; Plasswilm L; Putora PM
    Strahlenther Onkol; 2015 Oct; 191(10):778-86. PubMed ID: 25986251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Salvage radiotherapy for macroscopic local recurrences after radical prostatectomy : A national survey on patterns of practice.
    Dal Pra A; Panje C; Zilli T; Arnold W; Brouwer K; Garcia H; Glatzer M; Gomez S; Herrera F; Kaouthar K; Papachristofilou A; Pesce G; Reuter C; Vees H; Zwahlen DR; Engeler D; Putora PM
    Strahlenther Onkol; 2018 Jan; 194(1):9-16. PubMed ID: 28656373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ESTRO-ACROP recommendations for evidence-based use of androgen deprivation therapy in combination with external-beam radiotherapy in prostate cancer.
    Schmidt-Hegemann NS; Zamboglou C; Mason M; Mottet N; Hinnen K; De Meerleer G; Cozzarini C; Maingon P; Henry A; Spahn M; Cornford P; Belka C; Wiegel T
    Radiother Oncol; 2023 Jun; 183():109544. PubMed ID: 36813168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changing trends in national practice for external beam radiotherapy for clinically localized prostate cancer: 1999 Patterns of Care survey for prostate cancer.
    Zelefsky MJ; Moughan J; Owen J; Zietman AL; Roach M; Hanks GE
    Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):1053-61. PubMed ID: 15234039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The addition of low-dose-rate brachytherapy and androgen-deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated external-beam radiation therapy for high-risk prostate cancer.
    Shilkrut M; Merrick GS; McLaughlin PW; Stenmark MH; Abu-Isa E; Vance SM; Sandler HM; Feng FY; Hamstra DA
    Cancer; 2013 Feb; 119(3):681-90. PubMed ID: 22893254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Redefining high-risk prostate cancer based on distant metastases and mortality after high-dose radiotherapy with androgen deprivation therapy.
    Tendulkar RD; Reddy CA; Stephans KL; Ciezki JP; Klein EA; Mahadevan A; Kupelian PA
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1397-404. PubMed ID: 21665379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality indicators for prostate radiotherapy: are patients disadvantaged by receiving treatment in a 'generalist' centre?
    Freeman AR; Roos DE; Kim L
    J Med Imaging Radiat Oncol; 2015 Apr; 59(2):255-64. PubMed ID: 25345594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Practice patterns of primary EBRT with and without ADT in prostate cancer treatment.
    Schmidt B; Eapen RS; Cowan JE; Broering JM; Greene KL; Carroll PR; Cooperberg MR
    Prostate Cancer Prostatic Dis; 2019 Mar; 22(1):117-124. PubMed ID: 30171230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of the Rate of Adherence to International Guidelines for Androgen Deprivation Therapy with External-beam Radiation Therapy: A Population-based Study.
    Dell'Oglio P; Abou-Haidar H; Leyh-Bannurah SR; Tian Z; Larcher A; Gandaglia G; Fossati N; Shariat SF; Capitanio U; Briganti A; Montorsi F; Graefen M; Saad F; Karakiewicz PI
    Eur Urol; 2016 Sep; 70(3):429-35. PubMed ID: 26951945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term androgen deprivation, with or without radiotherapy, in locally advanced prostate cancer: updated results from a phase III randomised trial.
    Sargos P; Mottet N; Bellera C; Richaud P
    BJU Int; 2020 Jun; 125(6):810-816. PubMed ID: 30946523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
    Demanes DJ; Brandt D; Schour L; Hill DR
    Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose radiotherapy with or without androgen deprivation therapy for intermediate-risk prostate cancer: cancer control and toxicity outcomes.
    Edelman S; Liauw SL; Rossi PJ; Cooper S; Jani AB
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1473-9. PubMed ID: 22245201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is androgen deprivation therapy necessary in all intermediate-risk prostate cancer patients treated in the dose escalation era?
    Castle KO; Hoffman KE; Levy LB; Lee AK; Choi S; Nguyen QN; Frank SJ; Pugh TJ; McGuire SE; Kuban DA
    Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):693-9. PubMed ID: 22836052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiotherapy with or without androgen deprivation therapy in intermediate risk prostate cancer?
    Amit U; Lawrence YR; Weiss I; Symon Z
    Radiat Oncol; 2019 Jun; 14(1):99. PubMed ID: 31182119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continued benefit to androgen deprivation therapy for prostate cancer patients treated with dose-escalated radiation therapy across multiple definitions of high-risk disease.
    Stenmark MH; Blas K; Halverson S; Sandler HM; Feng FY; Hamstra DA
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e335-44. PubMed ID: 21645976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interval to biochemical failure predicts clinical outcomes in patients with high-risk prostate cancer treated by combined-modality radiation therapy.
    Shilkrut M; McLaughlin PW; Merrick GS; Vainshtein JM; Feng FY; Hamstra DA
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(4):721-8. PubMed ID: 23664325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postoperative radiotherapy for prostate cancer: a comparison of four consensus guidelines and dosimetric evaluation of 3D-CRT versus tomotherapy IMRT.
    Malone S; Croke J; Roustan-Delatour N; Belanger E; Avruch L; Malone C; Morash C; Kayser C; Underhill K; Li Y; Malone K; Nyiri B; Spaans J
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):725-32. PubMed ID: 22444999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Radiation therapy of locally advanced prostate cancer].
    Schmidt-Hegemann NS; Li M; Eze C; Belka C; Ganswindt U
    Urologe A; 2017 Nov; 56(11):1402-1409. PubMed ID: 28983664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. External beam radiotherapy for prostate cancer.
    Pinkawa M
    Panminerva Med; 2010 Sep; 52(3):195-207. PubMed ID: 21045776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of concurrent androgen deprivation on fiducial marker migration in external-beam radiation therapy for prostate cancer.
    Tiberi DA; Carrier JF; Beauchemin MC; Nguyen TV; Béliveau-Nadeau D; Taussky D
    Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):e7-e12. PubMed ID: 22541962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.